Jenkem Technology (688356) Fundamentals 2026 — P/E 61.3x, Revenue Analysis | SniperIQ
Jenkem Technology (688356) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥4.5B, trading at ¥74.81 on the SHH. This SniperIQ fundamentals page covers Jenkem Technology's valuation (P/E 61.3x, P/B 3.4x), profitability (net margin 22.7%), revenue (¥318M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jenkem Technology's market cap?
Jenkem Technology (688356) has a market capitalization of approximately ¥4.5B, trading at ¥74.81 on the SHH. Market cap moves with the live share price.
What is Jenkem Technology's P/E ratio?
Jenkem Technology's trailing twelve-month P/E ratio is 61.3x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jenkem Technology?
Jenkem Technology runs a net profit margin of 22.7%, a gross margin of 102.0%, and an operating margin of 25.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jenkem Technology generate?
Jenkem Technology reported revenue of ¥318M for fiscal year 2025, with net income of ¥62M and earnings per share (EPS) of 1.02. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jenkem Technology pay a dividend?
Jenkem Technology offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jenkem Technology financially healthy?
Jenkem Technology carries a debt-to-equity ratio of 0.00x and a current ratio of 10.41x, with a market beta of 0.61. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jenkem Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jenkem Technology (688356) the key facts are: market cap ¥4.5B, P/E 61.3x, revenue ¥318M, 52-week range 66-118.68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jenkem Technology's full fundamentals live
Get Jenkem Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.